{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:06:30Z","timestamp":1789725990159,"version":"4.0.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.kint.2026.06.008","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:34:29Z","timestamp":1785782069000},"page":"1042-1043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Authors\u2019 response to \u201cAngiotensin receptor-neprilysin inhibitors for kidney protection in heart failure and chronic kidney disease: is there still a place?\u201d"],"prefix":"10.1016","volume":"110","author":[{"given":"Carolyn S.P.","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-0253","authenticated-orcid":false,"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadiya S.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Madero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.06.008_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2026.102943","article-title":"Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"14","author":"Lam","year":"2026","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.kint.2026.06.008_bib2","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.kint.2025.10.011","article-title":"Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"109","author":"Lam","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.06.008_bib3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.kint.2026.06.008_bib4","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2026.06.008_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/ejhf.3454","article-title":"Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: a systematic review and meta-analysis","volume":"27","author":"Nguyen","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kint.2026.06.008_bib6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/HJH.0000000000003972","article-title":"Efficacy and safety of sacubitril-valsartan in hypertension patients with end-stage kidney disease on maintenance dialysis: a meta-analysis","volume":"43","author":"Nguyen","year":"2025","journal-title":"J Hypertens"},{"key":"10.1016\/j.kint.2026.06.008_bib7","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2026.06.008_bib8","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41591-026-04313-w","article-title":"The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial","volume":"32","author":"Solomon","year":"2026","journal-title":"Nat Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826005004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826005004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:32:05Z","timestamp":1789723925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826005004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0085253826005004"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.06.008","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Authors\u2019 response to \u201cAngiotensin receptor-neprilysin inhibitors for kidney protection in heart failure and chronic kidney disease: is there still a place?\u201d","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.10.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.06.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Cardiology Foundation and International Society of Nephrology. Published by Elsevier Inc on behalf of American College of Cardiology and International Society of Nephrology","name":"copyright","label":"Copyright"}]}}